|
|
Vaccine Detail
|
MUC1 Peptide-Poly-ICLC Vaccine |
| Vaccine Information |
- Vaccine Name: MUC1 Peptide-Poly-ICLC Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: MUC-1 peptide (NCT03300817; NCT00986609; NCIT_C82417)
- Immunization Route: subcutaneous injection
- Description: This is a vaccine preparation containing mucus 1 (MUC1) peptide and the adjuvant poly-ICLC with potential immunostimulatory and antineoplastic activities. MUC1 peptide-poly-ICLC adjuvant vaccine may induce the host immune system to mount a cytotoxic T cell response against MUC1-expressing tumor cells. (NCIT_C82417) MUC1 peptide-poly-ICLC adjuvant vaccine in boosting systemic immunity to MUC1 in women with stage I-III 'triple-negative' [i.e., ER(-) PR(-) HER2/neu(-)] breast cancer. (NCT00986609) MUC1 peptide-Poly-ICLC vaccine could also work in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop the changes from normal to pre-cancer to cancer. (NCT03300817)
|
| Host Response |
|
|
| References |
NCIT_C82417: MUC1 Peptide-Poly-ICLC Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C82417]
NCT00986609: MUC1 Vaccine for Triple-negative Breast Cancer [https://clinicaltrials.gov/study/NCT00986609]
NCT03300817: MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer [https://clinicaltrials.gov/study/NCT03300817]
|
|
